WuXi Biologics To Build Vaccine Mfg Plant; Plans $3-Billion Supply Pact

By Emily Forster -

May 22, 2019

WuXi Biologics, a contract biologics manufacturer, has signed a letter of intent for a strategic partnership with an unnamed vaccine maker for a 20-year supply contract, estimated to be worth more than $3 billion. Under the letter of intent, WuXi Vaccines, a joint-venture company between WuXi Biologics and Shanghai-based Hile Bio-Technology, will build a dedicated vaccines-manufacturing facility to supply a commercial product to the unnamed client for the global market.

WuXi Vaccines’ business model is to create integrated platforms and contract development manufacturing organization models to assist global companies in developing and manufacturing vaccines.

Under the agreement, WuXi Vaccines will build a new vaccine-manufacturing facility for drug-substance manufacturing, drug-product manufacturing, and quality control labs. The facility will be dedicated to exclusively manufacture one vaccine product for an unnamed producer.

Source: WuXi Biologics